Abstract
Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
CNS & Neurological Disorders - Drug Targets
Title:Conference Report
Volume: 11 Issue: 3
Author(s): Stephen D. Skaper
Affiliation:
Abstract: Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
Export Options
About this article
Cite this article as:
D. Skaper Stephen, Conference Report, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672427
DOI https://dx.doi.org/10.2174/187152712800672427 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular microRNAs
Current Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Role of Dental Stem Cells in the Cellular Therapy of Cerebral Ischemia
Current Pharmaceutical Design Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Current Pharmaceutical Design An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry The Role of Neuroimaging in Our Understanding of the Suicidal Brain
CNS & Neurological Disorders - Drug Targets Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design